Search Results for “EC” – Page 168 – media

Ipsen receives approval from European Commission for Xermelo®

Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, announced that the European Commission(EC) has approved Xermelo® (telotristat ethyl) 250 mg three times a day (tid) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy.
- Source: Ipsen
- 488
- September 21, 2017
biopharmaceutical New Approvals SSA
China’s Import and Export Market of Obstetrics and Gynecology Equipment

Development of technology over the past couple of decades has led to societal and cultural development which in turn has resulted in awareness of issues such as the importance of women’s health. With vast improvements taking place in this field, obstetrics and gynecology equipment has experienced major changes.
- Source: Ddu
- 1,277
- September 20, 2017
export gynecology import Market Reports obstetrics
UOW researchers secure grant to develop new medical device for bedside brain monitoring

A University of Otago, Wellington (UOW) team has been awarded an MBIE Endeavour grant to develop a non-invasive and cost-effective device to diagnose and treat stroke and other brain injuries.
- Source: medicaldevices-business-review
- 679
- September 20, 2017
brain non-invasive Researches stroke
AstraZeneca and Aspen enter agreement for remaining rights to anaesthetics medicines

AstraZeneca announced that it has entered into an agreement with Aspen Global Incorporated (AGI), part of the Aspen Group, under which AGI will now acquire the residual rights to the established anaesthetic medicines comprising of Diprivan, EMLA, Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest.
- Source: Astrazeneca
- 472
- September 18, 2017
aggrement anaesthetic residual
Teva Receives FDA Priority Review for First Line Use of TRISENOX® (arsenic trioxide) in Patients with Low to Intermediate Risk Acute Promyelocytic Leukemia (APL)

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the U.S. Food and Drug Administration (FDA) has accepted for review the company’s supplemental New Drug Application (sNDA) for the use of TRISENOX® (arsenic trioxide) injection in combination with all-trans retinoic acid (ATRA) for induction of remission and consolidation in patients with newly diagnosed low or intermediate risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.
- Source: Tevapharm
- 562
- September 15, 2017
APL ATRA leukemia New Approvals TRISENOX
Apple is testing whether the Apple Watch can detect heart problems

Apple is working with partners to test whether its smartwatch can be used to detect common heart conditions, an effort that would make its device a "must have" for millions of people worldwide. The company is partnering up with a group of clinicians at Stanford, as well as telemedicine vendor American Well, to test whether Apple Watch's heart rate sensor can detect abnormal heart rhythms in a cohort of patients, according to two people familiar. The people requested anonymity as these plans have not yet been made public.
- Source: finance.yahoo
- 826
- September 14, 2017
abnormal heart rhythm Arrhythmias Company Insight
Novartis Phase III study demonstrates adjuvant Tafinlar® + Mekinist® reduced the risk of disease recurrence by 53%

Novartis today announced results from a Phase III study of 870 patients with stage III BRAF V600E/K mutation-positive melanoma after complete surgical resection treated with the combination of Tafinlar® (dabrafenib) + Mekinist® (trametinib) .
- Source: Novartis
- 822
- September 13, 2017
Mekinist Phase Tafinlar
Checkpoint Therapeutics Receives Orphan Drug Designation for CK-101 for the Treatment of EGFR Mutation-Positive Non-Small Cell Lung Cancer

The U.S. Food and Drug Administration (FDA) has granted Checkpoint Therapeutics, Inc. (“Checkpoint”) (CKPT)'s Orphan Drug Designation to CK-101 (also known as RX518), the Company’s third-generation epidermal growth-factor receptor (EGFR) inhibitor, for the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC).
- Source: finance.yahoo
- 499
- September 12, 2017
FDA inhibitor NSCLC
Merck to Acquire Rigontec, Expanding Cancer Immunotherapy Franchise

Merck & Co. has agreed to acquire Rigontec for up to €464 million (about $554 million), in a deal that will expand the cancer immunotherapy franchise of the Keytruda® (pembrolizumab) developer with a three-year-old Bonn University spinout whose technology targets the retinoic acid-inducible gene I (RIG-I) pathway.
- Source: genengnews
- 539
- September 11, 2017
acquisition immunotherapy Market Views RIG-I
Sanofi wins tentative FDA nod for Admelog insulin lispro injection

Sanofi announced that the U.S. Food and Drug Administration (FDA) granted tentative approval for Admelog® (insulin lispro injection) 100 Units/mL, a rapid-acting human insulin analog. Admelog is indicated to improve glycemic control in adults and children with diabetes mellitus.
- Source: yahoo
- 737
- September 7, 2017
Company Insight diabetes FDA insulin New Approvals

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.